Xencor (XNCR) reported a Q4 net loss of $0.62 per diluted share, wider than its loss of $0.43 year earlier.
Analysts surveyed by FactSet expected a loss of $0.78.
Revenue for the quarter ended Dec. 31 was $52.8 million, compared with $51 million a year earlier.
Analysts surveyed by FactSet expected $20.4 million.
The clinical-stage biopharmaceutical company said it expects to end 2025 with cash, cash equivalents and marketable debt securities in a range of $535 million to $585 million, and to have cash to fund research, development programs and operations into 2028.
Price: 14.81, Change: +0.43, Percent Change: +2.99
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。